The Claim
In overweight/obese adults, a 12-week intervention with once-weekly semaglutide and lifestyle advice resulted in a decrease in visceral fat mass by 0.36 kg (21.3% relative reduction), which was proportionally greater than the 0.37 kg (16.1%) reduction in subcutaneous fat (difference of 5.16 percentage points, P=0.009).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Overweight and obese adults who received weekly semaglutide injections and lifestyle advice for 12 weeks lost visceral fat by 21.3% and subcutaneous fat by 16.1%. The proportional reduction in visceral fat was significantly greater than in subcutaneous fat.
See the scientific wording
During a 12-week intervention with once-weekly semaglutide and lifestyle advice in overweight/obese adults, visceral fat mass decreased by 0.36 kg (21.3% relative reduction), which was proportionally greater than the 0.37 kg (16.1%) reduction in subcutaneous fat (difference of 5.16 percentage points, P=0.009).
Semaglutide attaches to GLP-1 receptors on fat cells, which tells the body to break down fat for energy. This happens more in the deep belly fat because that fat is more active and has more receptors, so it shrinks faster than the fat under the skin.
What the research says
1 studyStudy: Effects of once-weekly semaglutide on regional body composition in overweight or obese adults
The study found that semaglutide plus lifestyle changes reduced deep belly fat by about 21% and fat under the skin by about 16%, matching the claim that belly fat decreased at a faster rate.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.